• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Group

14.56 EUR+0.97 %19/8 16:15
14,486 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+0.97 %
+15.92 %
+5.20 %
-20.52 %
-35.00 %
-39.46 %
-35.40 %
-76.13 %
+666.32 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
424.67M EUR
Turnover
748.78K EUR
P/E (adj.) (26e)
17.75
EV/EBIT (adj.) (26e)
19.77
P/B (26e)
1.98
EV/S (26e)
3.38
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
20.00 EUR
Updated
2026-04-29
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-04-29

Latest extensive report

Released: 2025-01-21

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
I wrote a short analysis on Revenio for Salkunrakentaja. Revenio suffered a complete knockout following the Visionix acquisition
8/14/2026, 6:44 AM
by Tomi Lindell
37
Inderes Revenion iCare DRSplus mukana FDA-hyväksytyssä tekoälyratkaisussa... Revenio Group Oyj | Lehdistötiedote | 17.08.2026 klo 09:00:00 EESTRevenion iCare DRSplus -silmänpohjakamera on mukana Yhdysvalloissa FDA:n hyväksymässä tekoälypohjaisessa ratkaisussa, jossa ...
8/17/2026, 6:07 AM
by Tunturisusi
21
OP has updated its estimates (see Zijoittaja’s tweet) The image shows a target price of €18.0 and a reiterated Buy rating. P/E ratios of 14/10/8 for the years '26/'27/'28. Apparently, the market doesn’t believe in the synergies, and the upcoming share issue is also a poison pill....
8/17/2026, 11:47 AM
by Opa
15
Inderes – 17 Aug 26 Revenio: iCaren tekoälykumppani sai vihreää valoa FDA:lta - Inderes Ensimmäinen FDA-hyväksyntä iCare-kameran ja tekoälyn yhdistelmälle poistaa epävarmuutta ja tukee laitemyynnin kasvua Yhdysvalloissa. This is likely what caused the positive momentum already on...
8/17/2026, 7:03 AM
by Juha Kinnunen
15
Clearly the forum knows better, and the analyst has been on vacation. I suspect many others have been too. I wonder if some confirmation has come through now that the company is issuing a statement, or if they have also just returned from their vacation?
8/17/2026, 7:12 AM
by Juha Kinnunen
14
@Juha_Kinnunen , I mentioned the approval iHealthscreen received for DRS Plus on the forum over a month ago, so it’s not exactly fresh news. Positive, certainly, absolutely.
8/17/2026, 7:07 AM
by Sheikki
10
Something new regarding Icare will be announced in September at the trade fair in London. I won’t speculate any further, but at first glance, it just looks like an updated model. iCare iCare at ESCRS 2025 Visit iCare at ESCRS in Copenhagen, Denmark, on 12-16 September, 2025. Stop...
yesterday
by Pandakarhu
7
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8/9
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

Revenio: iCare's AI partner received green light from FDA
Analyst Comment2026-08-17 09:52 by
Juha Kinnunen

Revenio: iCare's AI partner received green light from FDA

The first FDA approval for the combination of the iCare imaging device and AI removes uncertainty and supports growth in device sales in the United States.

Revenio Group
Press release2026-08-17 08:00

Revenio’s iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Revenio Group
Revenio, Audiocast, Q2'26
Webcast2026-09-08 14:00

Revenio, Audiocast, Q2'26

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-12 12:00

Jukka Kainulainen starts as Revenio CFO on August 24, 2026

Revenio Group
Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership
Analyst Comment2026-08-07 07:57 by
Juha Kinnunen

Revenio: iCare strengthens its foothold in the US screening market with EyeCheq partnership

The strategic partnership can expand the availability of iCare devices in the United States.

Revenio Group
Press release2026-08-06 15:00

Revenio Group’s iCare and EyeCheq announce strategic partnership and minority investment

Revenio Group
Regulatory press release2026-08-05 13:00

Revenio’s updated Disclosure Policy is published

Revenio Group
Revenio: Visionix integration progresses as planned
Analyst Comment2026-08-03 08:04 by
Juha Kinnunen

Revenio: Visionix integration progresses as planned

The company aims for an EBITDA improvement of over 20 MEUR through Visionix synergies by the end of 2029.

Revenio Group
Press release2026-07-31 11:50

Revenio provides an update on the Visionix integration progress and announces changes in the U.S. organization

Revenio Group
Regulatory press release2026-06-30 08:00

Revenio Group Corporation’s Board of Directors resolved on the long-term incentive plan’s performance period 2026–2028 and launch of a new restricted share plan

Revenio Group
Regulatory press release2026-06-12 09:00

Revenio Group Corporation: Managers' Transactions – Marc Abitbol Consulting Service Ltd.

Revenio Group
Regulatory press release2026-06-11 11:20

Correction: Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release2026-06-10 18:00

Changes to the publication dates of Revenio’s financial reports in 2026

Revenio Group
Regulatory press release2026-06-10 18:00

Board of Directors of Revenio has established Technology and Integration Committees

Revenio Group
Regulatory press release2026-06-02 09:00

Revenio Group Corporation: Managers' Transactions – Marc Abitbol

Revenio Group
Regulatory press release2026-06-02 09:00

Revenio Group Corporation: Managers' Transactions – Caravelle Capital SAS

Revenio Group
Regulatory press release2026-05-29 15:00

Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act

Revenio Group
Regulatory press release2026-05-29 08:45

New shares issued in Revenio’s directed share issue have been registered with the Finnish Trade Register

Revenio Group
Revenio: Visionix acquisition completed slightly faster than expected
Analyst Comment2026-05-29 08:59 by
Juha Kinnunen

Revenio: Visionix acquisition completed slightly faster than expected

The slightly faster-than-expected closing of the Visionix transaction mechanically raises this year's revenue and earnings estimates.

Revenio Group
Regulatory press release2026-05-28 12:34

Revenio introduces new Leadership Team following the completion of the Visionix transaction

Revenio Group